L G Lum
Overview
Explore the profile of L G Lum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
789
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al-Kadhimi Z, Gul Z, Abidi M, Lum L, Deol A, Chen W, et al.
Bone Marrow Transplant
. 2017 Jun;
52(9):1304-1310.
PMID: 28581472
Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II...
2.
Gul Z, Van Meter E, Abidi M, Ditah I, Abdul-Hussein M, Deol A, et al.
Bone Marrow Transplant
. 2015 Jan;
50(3):432-7.
PMID: 25599169
Multiple reports have shown that low absolute lymphocyte count at day 30 (ALC30) after allogeneic hematopoietic SCT (AHSCT) is associated with higher risk of disease relapse and worse OS. However,...
3.
Ratanatharathorn V, Deol A, Ayash L, Cronin S, Bhutani D, Lum L, et al.
Bone Marrow Transplant
. 2014 Oct;
50(1):106-12.
PMID: 25285804
We performed a retrospective analysis of the outcome of 197 consecutive unrelated donor transplant recipients who received GVHD prophylaxis either TM regimen (tacrolimus and mycophenolate) (121 patients) or TM/ATG-G regimen...
4.
Lum L, Thakur A, Pray C, Kouttab N, Abedi M, Deol A, et al.
Bone Marrow Transplant
. 2013 Sep;
49(1):73-9.
PMID: 24056738
A pilot phase I clinical trial involving 15 infusions of anti-CD3 × anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T cells (aATC) and low-dose IL-2 was conducted in three non-Hodgkin's lymphoma (NHL)...
5.
Deol A, Abrams J, Masood A, Al-Kadhimi Z, Abidi M, Ayash L, et al.
Bone Marrow Transplant
. 2013 Mar;
48(8):1112-6.
PMID: 23474805
We report the long-term follow up of 49 patients (pts) enrolled on plerixafor compassionate use protocol. Thirty-seven pts (76%) had failed one previous mobilization attempt, while 12 (24%) had failed...
6.
Norkin M, Ratanatharathorn V, Ayash L, Abidi M, Al-Kadhimi Z, Lum L, et al.
Bone Marrow Transplant
. 2010 Nov;
46(10):1353-6.
PMID: 21113188
Large pericardial effusion (LPE) leading to cardiac tamponade is a rare complication described in patients undergoing SCT. This complication is considered to be a manifestation of chronic GVHD; however its...
7.
Berz D, Colvin G, McCormack E, Winer E, Karwan P, Colvin L, et al.
Transplant Proc
. 2009 Nov;
41(9):3863-7.
PMID: 19917402
Background: Tandem high-dose melphalan therapy with autologous peripheral stem cell support has emerged as the standard of care for patients without prohibitive comorbidities. Mucositis and gastrointestinal side effects are the...
8.
Quesenberry P, Colvin G, Abedi M, Lambert J, Moore B, Demers D, et al.
Bone Marrow Transplant
. 2003 Aug;
32 Suppl 1:S19-22.
PMID: 12931234
The marrow hematopoietic stem cell is currently being redefined as to all aspects of its phenotype and its total differentiation capacity. This redefinition now includes its plasticity as to production...
9.
Ren-Heidenreich L, Lum L
Curr Gene Ther
. 2002 Jul;
1(3):253-5.
PMID: 12109140
A promising strategy for cancer treatment is adoptive gene therapy/immunotherapy by genetically modifying T lymphocytes with a chimeric receptor (ch-TCR) so that cytotoxic T lymphocytes (CTL) can target and lyse...
10.
Lum L, LeFever A, Treisman J, Garlie N, Hanson Jr J
J Immunother
. 2001 Nov;
24(5):408-19.
PMID: 11696696
Anti-CD3/anti-CD28 monoclonal antibody-coactivated T cells (COACTs) proliferate, secrete tumoricidal cytokines, and mediate non-major histocompatibility complex (MHC)-restricted cytotoxicity. This phase I study was done to determine the safety, maximum tolerated dose,...